The Effect of RECO-18 on Infertile Women Undergoing in Vitro Fertilization-embryo Transfer

NCT05412147 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-06-09

No results posted yet for this study

Summary

How to improve the fertility of infertile women has become a hot topic in the field of assisted reproduction. Animal experiment has shown that RECO-18 significantly improved the female fertility in mice, and the specific mechanism was related to reducing follicular atresia, promoting follicle development and improving oocyte quality. Therefore the investigators aim to conduct a pilot study to explore the effect of RECO-18 in infertile women undergoing assisted reproduction treatment. This study is a prospective, randomized, controlled clinical study. The treatment group takes RECO-18 while the control group takes the multi-vitamins. The primary indicator is the ongoing pregnancy rate at 12 weeks' gestation; the secondary indicators are the number of oocytes retrieved, the normal fertilization rate and the rate of high quality embryos, implantation rate, clinical pregnancy rate, and early miscarriage rate.

Conditions

  • Fertility Disorders
  • Infertility, Female

Interventions

DIETARY_SUPPLEMENT

RECO-18

4 pills daily, oral

DIETARY_SUPPLEMENT

Multi-vitamins

one tablet daily, oral

Sponsors & Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Dongzi Yang, doctor · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  • Hui Chen, doctor · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  • Ruiqi Li, doctor · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  • Xiaoli Chen, doctor · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  • Lin Li, doctor · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  • Ping Pan, doctor · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  • Jia Huang, doctor · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-31
Primary Completion
2023-04-30
Completion
2023-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05412147 on ClinicalTrials.gov